Gsk (GSK) Non-Current Deferred Tax Liability (2016 - 2025)
Historic Non-Current Deferred Tax Liability for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$526.1 million.
- Gsk's Non-Current Deferred Tax Liability fell 3773.21% to -$526.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$526.1 million, marking a year-over-year decrease of 3773.21%. This contributed to the annual value of -$488.3 million for FY2024, which is 22623.18% down from last year.
- Latest data reveals that Gsk reported Non-Current Deferred Tax Liability of -$526.1 million as of Q3 2025, which was down 3773.21% from -$512.3 million recorded in Q2 2025.
- Gsk's Non-Current Deferred Tax Liability's 5-year high stood at $4.8 billion during Q4 2021, with a 5-year trough of -$5.1 billion in Q3 2021.
- Over the past 5 years, Gsk's median Non-Current Deferred Tax Liability value was -$490.3 million (recorded in 2024), while the average stood at -$1.0 billion.
- As far as peak fluctuations go, Gsk's Non-Current Deferred Tax Liability soared by 9625.75% in 2022, and later tumbled by 23345.18% in 2023.
- Quarter analysis of 5 years shows Gsk's Non-Current Deferred Tax Liability stood at $4.8 billion in 2021, then plummeted by 92.93% to $339.0 million in 2022, then increased by 13.87% to $386.0 million in 2023, then tumbled by 227.02% to -$490.3 million in 2024, then dropped by 7.31% to -$526.1 million in 2025.
- Its Non-Current Deferred Tax Liability stands at -$526.1 million for Q3 2025, versus -$512.3 million for Q2 2025 and -$508.8 million for Q1 2025.